Home > Resources > Company Profiles > Catalyst Pharmaceutical Partners, Incorporated

Catalyst Pharmaceutical Partners, Incorporated (CPRX)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Patrick McEnany , CEO/Chairman of the Board/Director/President/Founder
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Patrick McEnany, CEO/Chairman of the Board/Director/President/Founder

355 Alhambra Circle

Suite 1370

Coral Gables, FL 33134

US Map it

Phone: (305) 529-2522

Fax: (305) 529-0933

www.catalystpharma.com



Overview

A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.

Employees

Number of Employees: 7
Revenue per Employee: $0

Top Executives

M. Douglas Winship, Vice President, Divisional
Charles B. O'Keeffe, Director/Other Corporate Officer
Alicia Grande, CPA, CMA, Chief Accounting Officer/Controller

Jack Weinstein, CFO/Vice President/Treasurer
Dr. Steven R. Miller, Ph.D., Vice President, Divisional
Dr. Charles W. Gorodetzky, M.D., Ph.D., Chief Medical Officer

Board of Directors

Dr.David S. Tierney, M.D., Director
Charles B. O'Keeffe, Director/Other Corporate Officer
Philip H. Coelho, Director

Dr.Hubert E. Huckel, M.D., Director/Founder
Jack Weinstein, CFO/Vice President/Treasurer
Milton J. Wallace, Director

Financials

Quarterly
Annual

Income Statement 09/2008 06/2008 03/2008 12/2007
Sales -8.23 K. -8.21 K. -7.68 K. -3.41 K.
Gross Operating Profit 8.23 K. 8.21 K. 7.68 K. 3.41 K.
Operating Income before D & A (EBITDA) -2.46 Mil. -1.72 Mil. -1.13 Mil. -947.01 K.
Total Income Before Interest Expenses (EBIT) -2.38 Mil. -1.58 Mil. -944.94 K. -734.35 K.
Total Net Income -2.38 Mil. -1.58 Mil. -944.94 K. -734.35 K.
Basic EPS, Total -0.19 -0.13 -0.07 -0.06
Diluted EPS, Total -0.19 -0.13 -0.07 -0.06

BALANCE STATEMENT 09/2008 06/2008 03/2008 12/2007
Cash and Equivalents 13.08 Mil. 14.72 Mil. 15.94 Mil. 16.89 Mil.
Total Assets 13.4 Mil. 15.34 Mil. 16.53 Mil. 17.45 Mil.
Total Liabilities 740.14 K. 438.08 K. 303.28 K. 405.05 K.
Total Capitalization 12.75 Mil. 15 Mil. 16.32 Mil. 17.19 Mil.

Cash Flow 09/2008 06/2008 03/2008 12/2007
Net Cash From Continuing Operations -2.84 Mil. -1.22 Mil. -4.42 Mil. -3.49 Mil.
Net Cash From Investing Activities -1.34 K. -1.34 K. -65.87 K. -55.92 K.
Net Cash From Financing Activities -19 K. -2.01 K. 0 0
Net Change in Cash & Cash Equivalents -2.86 Mil. -1.23 Mil. -4.49 Mil. -3.55 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006
Sales -15.76 K. -4.93 K. -1.37 K.
Gross Operating Profit 15.76 K. 4.93 K. 1.37 K.
Operating Income before D & A (EBITDA) -5.01 Mil. -2.9 Mil. -1.82 Mil.
Total Income Before Interest Expenses (EBIT) -4.14 Mil. -2.73 Mil. -1.81 Mil.
Total Net Income -4.14 Mil. -2.73 Mil. -1.81 Mil.
Basic EPS, Total -0.33 -0.36 -0.29
Diluted EPS, Total -0.33 -0.36 -0.29

BALANCE STATEMENT 2008 2007 2006
Cash and Equivalents 15.94 Mil. 20.43 Mil. 771.13 K.
Total Assets 16.53 Mil. 20.59 Mil. 771.57 K.
Total Liabilities 303.28 K. 772.85 K. 342.99 K.
Total Capitalization 16.32 Mil. 19.85 Mil. 446.46 K.

Cash Flow 2008 2007 2006
Net Cash From Continuing Operations -4.42 Mil. -1.18 Mil. -455.36 K.
Net Cash From Investing Activities -65.87 K. -21.05 K. -3.94 K.
Net Cash From Financing Activities 0 20.86 Mil. 1.05 Mil.
Net Change in Cash & Cash Equivalents -4.49 Mil. 19.66 Mil. 587.22 K.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
RXElite, Incorporated
41.46 Mil.
Lotus Pharmaceuticals, Incorporated
37.41 Mil.
Isolagen, Inc.
27.1 Mil.
Pro-Pharmaceuticals, Inc.
17.36 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented